These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 32776313)

  • 1. Open-label non-mandatory transitioning from originators to biosimilars in routine clinical care.
    Provenzano G; Arcuri C; Miceli MC
    Clin Rheumatol; 2021 Jan; 40(1):425-427. PubMed ID: 32776313
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis.
    Ditto MC; Parisi S; Priora M; Sanna S; Peroni CL; Laganà A; D'Avolio A; Fusaro E
    Sci Rep; 2020 Sep; 10(1):16178. PubMed ID: 32999362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uptake and Spending on Biosimilar Infliximab and Etanercept After New Start and Switching Policies in Canada: An Interrupted Time Series Analysis.
    McClean AR; Cheng L; Bansback N; Clement F; Tadrous M; Harrison M; Law MR
    Arthritis Care Res (Hoboken); 2023 Sep; 75(9):2011-2021. PubMed ID: 36752358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GP2015: An Etanercept Biosimilar.
    Deeks ED
    BioDrugs; 2017 Dec; 31(6):555-558. PubMed ID: 28940172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis.
    Lindström U; Glintborg B; Di Giuseppe D; Nordström D; Aarrestad Provan S; Gudbjornsson B; Askling J; Lund Hetland M; Aaltonen K; Krogh NS; Geirsson AJ; Jacobsson LTH
    RMD Open; 2019; 5(2):e001079. PubMed ID: 31749988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etanercept biosimilars.
    Azevedo VF; Galli N; Kleinfelder A; D'Ippolito J; Urbano PC
    Rheumatol Int; 2015 Feb; 35(2):197-209. PubMed ID: 24980068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Benucci M; Gobbi FL; Guiducci S; Foti R; Mosca M; Goletti D
    Semin Arthritis Rheum; 2017 Oct; 47(2):183-192. PubMed ID: 28413099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The nocebo effect challenges the non-medical infliximab switch in practice.
    Boone NW; Liu L; Romberg-Camps MJ; Duijsens L; Houwen C; van der Kuy PHM; Janknegt R; Peeters R; Landewé RBM; Winkens B; van Bodegraven AA
    Eur J Clin Pharmacol; 2018 May; 74(5):655-661. PubMed ID: 29368188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumor necrosis factor α: originators
    Gioia C; Picchianti Diamanti A; Perricone R; Chimenti MS; Afeltra A; Navarini L; Migliore A; Massafra U; Bruzzese V; Scolieri P; Meschini C; Paroli M; Caccavale R; Scapato P; Scrivo R; Conti F; Laganà B; Di Franco M
    Reumatismo; 2023 Dec; 75(4):. PubMed ID: 38115772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic treatment of psoriatic arthritis and axial spondyloarthritis with traditional biologic and non-biologic DMARDs.
    Soriano ER; Acosta-Felquer ML; Luong P; Caplan L
    Best Pract Res Clin Rheumatol; 2014 Oct; 28(5):793-806. PubMed ID: 25488785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of etanercept biosimilar SB4 in maintaining low disease activity in patients with psoriatic arthritis switched from etanercept originator: an open-label one year study.
    Bonifati C; De Felice C; Lora V; Morrone A; Graceffa D
    J Dermatolog Treat; 2020 Nov; 31(7):687-691. PubMed ID: 30985223
    [No Abstract]   [Full Text] [Related]  

  • 12. Changes in the use patterns of bDMARDs in patients with rheumatic diseases over the past 13 years.
    Sánchez-Piedra C; Sueiro-Delgado D; García-González J; Ros-Vilamajo I; Prior-Español A; Moreno-Ramos MJ; Garcia-Magallon B; Calvo-Gutiérrez J; Perez-Vera Y; Martín-Domenech R; Ruiz-Montesino D; Vela-Casasempere P; Expósito L; Sánchez-Alonso F; González-Davila E; Díaz-González F
    Sci Rep; 2021 Jul; 11(1):15051. PubMed ID: 34302036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective serum level of etanercept biosimilar and effect of antidrug antibodies on drug levels and clinical efficacy in Chinese patients with ankylosing spondylitis.
    Dong Y; Li P; Xu T; Bi L
    Clin Rheumatol; 2019 Jun; 38(6):1587-1594. PubMed ID: 30747393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
    Rossini M; Viapiana O; Orsolini G; Fracassi E; Idolazzi L; Gatti D; Adami S; Govoni M
    Reumatismo; 2015 Mar; 66(4):285-303. PubMed ID: 25829189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of continuation rates with three TNFα antagonists (adalimumab, infliximab, etanercept) in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: Retrospective 10-year study.
    Batteux B; Devauchelle A; Boyard PL; Sejourné A; Fardellone P; Goëb V
    Joint Bone Spine; 2016 Oct; 83(5):607-9. PubMed ID: 26919803
    [No Abstract]   [Full Text] [Related]  

  • 17. Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis.
    Chadwick L; Zhao S; Mysler E; Moots RJ
    Curr Rheumatol Rep; 2018 Nov; 20(12):84. PubMed ID: 30411183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polychondritis in a Patient With Ankylosing Spondylitis on an Anti-TNF-α Biosimilar Agent.
    Duro T; Li S; Jose D; Khawar T
    J Clin Rheumatol; 2021 Dec; 27(8S):S656. PubMed ID: 35073638
    [No Abstract]   [Full Text] [Related]  

  • 19. The persistence of golimumab compared to other tumour necrosis factor-α inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si.
    Rotar Ž; Tomšič M; Praprotnik S;
    Clin Rheumatol; 2019 Feb; 38(2):297-305. PubMed ID: 30324406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilars for the treatment of psoriatic arthritis.
    Cantini F; Benucci M; Li Gobbi F; Franchi G; Niccoli L
    Expert Rev Clin Immunol; 2019 Nov; 15(11):1195-1203. PubMed ID: 31625769
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.